Physician profile
John Ryder
NPI 1497165161
$1,596.78
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $92.05 · 2020: $15.46 · 2021: $15.85 · 2022: $559 · 2023: $889 · 2024: $24.64.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $914.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $914.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $493.61 | 2022-2023 | Vraylar |
| Otsuka America Pharmaceutical, INC. | $254.55 | 2019-2023 | Rexulti, Abilify Maintena |
| Neuronetics, INC. | $222.74 | 2022 | |
| Corium, LLC | $132.21 | 2022-2023 | Azstarys |
| Axsome Therapeutics, INC. | $116.38 | 2023 | Auvelity |
| Alkermes, INC. | $95.29 | 2022-2023 | Lybalvi |
| Almatica Pharma LLC | $84.70 | 2022-2023 | Gralise |
| Ironshore Pharmaceuticals INC. | $73.94 | 2019-2023 | Jornay Pm |
| Tris Pharma INC | $25.33 | 2019 | |
| Tempus Ai, INC | $24.64 | 2024 | |
| Arbor Pharmaceuticals, INC. | $24.48 | 2019 | |
| Janssen Pharmaceuticals, INC | $18.14 | 2022 | |
| Jazz Pharmaceuticals INC. | $15.46 | 2020 | |
| Neos Therapeutics, LP | $15.31 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Ryder listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.